⚗️ biochemistry

Covalent remodeling of CRBN creates a non-canonical neosubstrate interface with NTAQ1

This study demonstrates that the molecular glue degrader EM12-FS covalently remodels cereblon (CRBN) at His353 to create a novel, non-canonical interface that enables the selective recruitment and degradation of the neosubstrate NTAQ1, thereby expanding the scope of induced-proximity pharmacology through site-specific synthetic modification.

Original authors: de la Pena, A. H., Cruite, J. T., Che, J., Matyskiela, M. E., Chamberlain, P. P., Fischer, E. S., Jones, L. H.

Published 2026-07-15

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: de la Pena, A. H., Cruite, J. T., Che, J., Matyskiela, M. E., Chamberlain, P. P., Fischer, E. S., Jones, L. H.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body has a massive, high-tech recycling plant called the Proteasome. Its job is to take out the trash—specifically, old or broken proteins that clutter up the cell. But this plant doesn't just grab anything; it needs a specific "tag" to know what to throw away. Usually, a special team of workers called E3 ligases (specifically a team led by a protein named CRBN) acts as the tagger. They grab a piece of trash, stick a "destroy me" sticker (ubiquitin) on it, and send it to the shredder.

For years, scientists have had a set of keys called IMiDs (drugs like thalidomide) that fit into CRBN's lock. When these keys turn, they reshape the lock just enough to grab a specific type of trash: proteins with a special "G-loop" handle. This has been the only way to trick CRBN into grabbing new targets.

But what if you wanted to grab a piece of trash that doesn't have that G-loop handle? The old keys just wouldn't fit.

The Big Discovery: A Covalent "Super-Glue" Key
In this study, a team of researchers at Neomorph Inc. and Harvard Medical School tried a bold new idea. Instead of just turning the lock, they decided to permanently modify the lock itself.

They designed a special molecule called EM12-FS. Think of this molecule as a key with a tiny, super-strong "glue" tip (a fluorosulfate group). When this key slides into CRBN, it doesn't just sit there; it chemically bonds to a specific part of the lock called His353 (a histidine amino acid).

This isn't a gentle nudge; it's a permanent remodel. The glue forces His353 to snap into a completely new position. The researchers found that this new shape creates a brand-new surface that looks nothing like the old IMiD surface.

The New Target: NTAQ1
Because of this new shape, CRBN can now grab a completely different piece of trash: a protein called NTAQ1. Before this, NTAQ1 was invisible to CRBN. It's a protein that starts the "Arg/N-degron" pathway, but nobody knew how to make CRBN target it until now.

The team used a super-powerful microscope called cryo-EM (which takes 3D pictures of molecules at near-atomic resolution) to see exactly what happened. They captured a snapshot of the whole team working together: NTAQ1 + EM12-FS + CRBN + DDB1.

Here is the cool part of the picture they found:

The new position of the glued-down His353 creates a perfect spot for NTAQ1 to sit.
Specifically, the modified His353 and a part of NTAQ1 called Phe126 lock together in a unique "T-shaped" embrace. It's like two puzzle pieces that only fit when one of them has been reshaped by the glue.
This new interface is so specific that the old, reversible keys (like lenalidomide) can't do it. In fact, the old keys would actually crash into NTAQ1 and fail to grab it.

Why the "Glue" Matters
The researchers tested two versions of their glue-key: EM12-SF and EM12-FS. They look almost identical, differing by just one oxygen atom. But that tiny difference changed the geometry of the "glue" tip.

EM12-FS worked perfectly. It glued His353 in the right spot, creating the new surface that grabbed NTAQ1.
EM12-SF failed. Even though it could still glue to His353, the angle was slightly off. This tiny misalignment meant the new surface didn't form correctly, and NTAQ1 was never recruited.

This proves a crucial rule: For this kind of "molecular glue" to work, the chemical reaction isn't enough. The reaction must force the protein into the exact right shape to hold the new target. If the shape is even a little bit wrong, the whole system fails.

What This Means
The authors show that by chemically remodeling CRBN, they can reprogram it to grab targets it was never designed to see. They explicitly ruled out the idea that the old, reversible drugs could do this; the structure proves that NTAQ1 is physically blocked from binding to the old CRBN shape.

This isn't just about NTAQ1. It suggests a whole new way to design drugs. Instead of looking for a perfect fit in a pre-existing pocket, scientists can now use covalent chemistry to build new pockets on demand. It's like taking a standard key, gluing a new piece of metal to it, and suddenly being able to open a door that was previously locked forever.

The team measured the structure at a resolution of 3.2 Å (angstroms) and confirmed the findings with biochemical tests and mutations. They found that if you change specific parts of NTAQ1 (like the Phe126 or Ile122 spots), the whole team falls apart. This confirms that the new interface is real and essential.

In short, this paper demonstrates that you can use a chemical "glue" to permanently reshape a protein's surface, creating a brand-new docking station for a target that was previously out of reach. It's a new strategy for "induced-proximity" pharmacology, opening the door to targeting proteins that were once considered impossible to reach.

Technical Summary: Covalent Remodeling of CRBN Creates a Non-Canonical Neosubstrate Interface with NTAQ1

Problem Statement
Immunomodulatory imide drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide function by binding to the substrate adaptor cereblon (CRBN), a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding remodels the CRBN surface to recruit neosubstrates for proteasomal degradation. However, the vast majority of known neosubstrates rely on a canonical "G-loop degron"—a $\beta$ -hairpin loop containing a critical glycine—to engage the IMiD–CRBN interface. This structural requirement limits the therapeutic landscape, leaving many proteins without conventional ligandable pockets considered undruggable. While covalent drug discovery often targets cysteine residues, the thalidomide-binding domain (TBD) of CRBN lacks a suitably positioned cysteine. The authors hypothesized that site-specific synthetic manipulation of other residues, specifically the histidine (His353) located at the tip of the CRBN "sensor loop," could mimic post-translational modifications to rewire protein interactions and recruit non-canonical substrates.

Methodology
The study utilized a rational design approach based on the IMiD derivative EM12, incorporating sulfonyl exchange electrophiles to target His353. Two specific modulators were synthesized: EM12-SF (sulfonyl fluoride) and EM12-FS (fluorosulfate).

Structural Biology: The authors determined the cryo-EM structure of the ternary complex comprising NTAQ1, EM12-FS, CRBN, and DDB1 to a resolution of 3.2 Å at the interface. To ensure the observed conformation reflected the engineered state, CRBN was covalently pre-labeled with EM12-FS prior to complex assembly.
Biochemical and Mutational Analysis: Ternary complex formation (TCF) and ubiquitination were assessed using High-Throughput Resonance Energy Transfer (HTRF) assays. Systematic mutagenesis of NTAQ1 residues was performed to define the determinants of complex stability and degradation.
Computational Modeling: Molecular mechanics-generalized Born surface area (MM-GBSA) calculations were employed to analyze the energetics of the interface and the impact of electrophile geometry on His353 positioning.

Key Results

Selective Degradation: While EM12-SF failed to induce detectable degradation, EM12-FS exclusively degraded N-terminal glutamine amidase 1 (NTAQ1), a previously unrecognized CRBN neosubstrate involved in the Arg/N-degron pathway. Covalent engagement of His353 was confirmed as a strict requirement for this activity.
Structural Mechanism: The cryo-EM structure revealed that the fluorosulfate group of EM12-FS forms an imidazylate with His353. This covalent modification repositions the His353 imidazole ring, eliminating a steric clash with NTAQ1 residue Ile122 that would otherwise prevent engagement by reversible IMiDs.
Non-Canonical Interface: The resulting interface is distinct from all reversible IMiD complexes. It is stabilized by a distinctive T-shaped C-H/ $\pi$ interaction between the polarized C-H of the sulfated His353 and the aromatic ring of NTAQ1 Phe126. NTAQ1 engages the complex primarily through residues at the periphery of its $\alpha$ - $\beta$ - $\alpha$ amidohydrolase fold, lacking the canonical G-loop degron.
Electrophile Geometry Sensitivity: Despite differing by only a single oxygen atom, EM12-SF and EM12-FS induce different orientations of His353. The specific geometry of the fluorosulfate warhead in EM12-FS is essential for enforcing the precise conformation required for productive ternary complex formation and hydrophobic contacts with Ile122 and Phe126.
Residue Determinants: Mutational analysis confirmed that hydrophobic residues (e.g., Phe126) are indispensable for TCF and ubiquitination. Other residues (e.g., Asp120, Asp121, Gln125, Arg157) modulate complex stability without directly contacting the compound.

Significance and Claims
The paper establishes that site-specific synthetic modification of CRBN can reprogram induced-proximity pharmacology to expand specificity beyond the G-loop degron. The authors claim that covalent remodeling of the CRBN sensor loop creates a non-canonical neosubstrate interface that enables the recruitment of substrates inaccessible to reversible IMiDs.

Key contributions include:

Proof of Concept: Demonstrating that covalent modification of a non-cysteine residue (His353) can generate a new ligandable surface with unique physicochemical properties.
Design Principle: Establishing that for covalent molecular glues, the electrophile must not only react but must enforce a specific, productive conformational state of the E3 ligase compatible with the intended substrate.
Therapeutic Expansion: Providing the first chemical probe (EM12-FS) for selectively targeting NTAQ1, facilitating mechanistic studies of its role in DNA repair and cancer, and offering a framework for engineering new degrader modalities that rewire signaling pathways by modifying E3 ligase surfaces.

More like this